Shots:           

•  ATTR-ACT is a P-III global study with three-arms 20mg or 80mg PO QD vs PBO- including patients with variant (ATTRm)- wild-type (ATTRwt)- or hereditary
•  ATTR-ACT results (N=441): Reduced all-cause mortality (29.5% vs. 42.9%); cardiovascular-related hospitalizations (0.48 vs 0.70) showing its efficacy- safety and tolerability enhancing QoL                
•  In Mar’18- Japan granted SAKIGAKE designation whereas in May’18 the US FDA granted FT & BT designation to Tafamidis for ATTR-CM indication

        Ref: Pfizer | Image:  Pfizer